Podcast

The Bioverge Podcast: Developing Next-Generation in Vivo Cell and Gene Therapies

David Johnson, Founder & CEO of GigaMune, sits down with Neil to discuss his company's efforts to develop in vivo cell and gene therapies to treat cancer and autoimmune conditions.

The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Podcast

The Bioverge Podcast: Addressing the Challenges of Chronic Liver Disease

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

Podcast

The Bioverge Podcast: Engineering Intelligence into Cell and Gene Therapies

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

Podcast

The Bioverge Podcast: Changing Drug Discovery with Transomics

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

Podcast

The Bioverge Podcast: Accelerating Timelines and The Bioverge Podcast: Improving Outcomes with a Predictive Precision Medicine Platform

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

Podcast

The Bioverge Podcast: A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

Podcast

The Bioverge Podcast: Curing Blindness with Cell Therapy

On this episode, Arnaud Lacoste, Chief Scientific Officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

Podcast

The Bioverge Podcast: From Bugs to Drugs

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

Health+Tech, Investing

Investment Case Study: Volumetric Acquired for Up To $400M

Volumetric has entered into an agreement for acquisition by 3D Systems for up to $400M.